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Abstract 
Increasing evidence indicates some G protein-coupled receptors function as a 
heterodimer, which provide a novel target for therapeutics investigation. 
However, study on the receptor-receptor interaction interface, a potent target 
on interfering dimer formation, are still limited. Here, using bioluminescence 
resonance energy transfer (BRET) combined with co-immunoprecipitation 
(Co-IP), we found a new constitutive GPCR heterodimer, apelin receptor 
(APJ)-orexin receptor type 1 (OX1R). Both APJ and OX1R co-internalized 
when constantly subjected to cognate agonist (apelin-13 or orexin-A) specific 
to either protomer. Combined with BRET and immunostaining, the in vitro 
synthesized transmembrane peptides (TMs) interfering experiments suggests 
that TM4 and 5 of APJ act as the interaction interface of the APJ-OX1R 
heterodimer, and co-internalization could be disrupted by these peptides as 
well. Our study not only provide new evidence on GPCR heterodimerization, 
but address a novel heterodimerization interface, which can be severed as a 
potential pharmacological target.  
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Introduction 
As the largest family of plasma membrane binding proteins, more than 800 
genes in human genome encode G protein-coupled receptors (GPCRs)[1]. 
GPCR play a pivotal role for the cell in sensing the extracellular signal. The 
signal is transmitted into the cell due to the association of the GPCRs with 
heterotrimeric G proteins, which in turn activates an extensive array of 
signaling pathways to regulate cell physiology. GPCR mediated signaling 
usually occurs in so called lipid rafts-rich in cholesterol and sphingolipid-which 
provide a small membrane domain for the dynamically interaction between 
each of the signaling components. Indeed, besides interaction with G proteins 
or beta-arrestins, increasing evidences indicate that GPCRs could associate 
into dimers or oligomers at the plasma membrane[2]. Therefore, at the 
molecular level, GPCR signaling is not only determined by the agonist binding, 
but also allosterically modulated by other receptors. Further characterization of 
the GPCR-GPCR interactions is critical for providing more information on 
GPCR functions and on therapeutic targets with less adverse effects[1-3].  
It has been suggested that GPCR heteromer should meet three criteria, 
including interaction (colocalization and physical interaction), gain of function 
(heteromers exhibit distinct properties from those of the protomers ) and loss 
of function (disruption the heteromer should lead to loss of the 
heteromer-specific properties)[4]. Demonstrating the physical interaction is an 
important first step. Furthermore, if one can figure out the interaction interface 
of the heteromer, it would be helpful to understand the interaction pattern of 
GPCRs, and on the other hand, to precisely target the interaction strength for 
the purpose of therapeutics. In the case of μ-opioid receptor (MOR) isoform 
μOR1D and gastrin-releasing peptide receptor (GRPR) heteromers, a 
membrane-permeable fusion peptide unique to μOR1D isoform targeting 
μOR1D-GRPR heteromer lead to a decrease in morphine-induced scratching 
without affecting morphine-induced analgesia[4, 5]. Similarly, systemically 
administration of transmembrane peptide of μOR1 fusion with TAT to 
interfering with the dimerization of μOR1 and δOR could enhance morphine 
analgesia and reduce the antinociceptive tolerance to morphine[6]. While in 
the brain, blockade the μOR1-δOR heteromerization abolished the 
antidepressant-like and anxiolytic-like actions of the δOR-agonist UFP-512[7]. 
In addition to heteromerization, homomerization could also be disrupted with 
synthetic peptides targeting the interaction interface such as rhodopsin[8]. 
Actually, dissection of the interaction interface and utility of synthetized 
transmembrane peptides to interrupt the dimer/oligomer is a potent tool to 
study the function of dimerization/oligomerization of GPCRs[4, 9]. However, 
study on interaction interface remains largely insufficient.  
OX1R and OX2R, two homologs of orexin (orexin-A and orexin B) receptor, 
have a widespread distribution in human brain, especially at hypothalamus, 
thalamus, hippocampus and some nuclei in midbrain and hindbrain[10]. 
Besides regulation of motivated behaviors, orexinergic system act as a crucial 
regulator in sleep-arousal, addiction, anxiety and depression[10-14]. APJ，with 
its cognate ligands apelin (apelin-13, apelin-17 and apelin-36), is another 
GPCR involved in controlling of neuroendocrine response to stress through 
hypothalamic-pituitary-adrenal (HPA) axis. In the brain, APJ are extensively 
distributed yet mainly at paraventricular nucleus (PVN) of thalamus, supraoptic 
nucleus (SON) of the hypothalamus, hippocampus and habenular nuclei[15]. 
Considering the comparable roles in humoral response to stress and partially 
overlapping distribution in the brain, we hypothesize that there may be an 
interaction between OXR and APJ. 
To test this hypothesis, using co-immunoprecipitation (Co-IP) and 
bioluminescence resonance energy transfer (BRET), we found that OX1R and 
APJ form a heterodimer, in which transmembrane (TM) α-helix 4 and 5 of APJ 
may work as an interface. In the stimulation experiments, either orexin-A or 
apelin-13, the corresponding cognate ligands of the two receptors, could result 
in the internalization of the heteromers, but the process can be disturbed by 
the TM peptides 4 and 5 of APJ. Together, these results robustly suggest that 
OX1R dimerize with APJ, in which TM 4 and 5 of APJ serve as an interface. 
 
Materials and methods 
Plasmid constructs 
Among all the plasmids used in the study, 3xHA-APJ, APJ-Venus[16], 
OX1R-Rluc (Renilla luciferase), KOR-Rluc, OX1R-Venus[17], KOR196-Rluc, 
NTSR1-Venus[18] were constructed in our laboratory previously. For 
constructs of OX1R-Myc and KOR-HA, hOX1R was amplified using primers 
(5’-CCGCTCGAGATGGAGCCCTCAGCCACC-3’ and 
5’-GGAATTCTCAGAGATCCTCTTCTGAGATGAGTTTTTGTTCGGGCAGCA
CTGTGGTGACG-3’) and cloned into Xho I / EcoR I of pcDAN3.1 (-), while 
hKOR amplified using primers 
(5’-CCGCTCGAGATGGACTCCCCGATCCAGA-3’ and 
5’-CCCAAGCTTTCAAGCGTAGTCCGGAACGTCGTACGGGTATGGTTTATT
CATCCCATCGA-3’) but cloned into Xho I / Hind III of pcDAN3.1 (-). Primers 
sequences underlined are tags. 
Cell culture and transfection 
HEK293T cells were cultured in DMEM medium (Gibco, 12100046) 
supplemented with 10% (v/v) fetal bovine serum (FBS) at 37 oC in an 
atmosphere of 5% CO2. Cells were plated in a 6-well plate at a concentration 
of 1×106 cells/well or in 10-cm-diameter flasks and cultured overnight prior to 
transfection. Cells were transiently transfected using LipofectamineTM 2000 
transfection reagent (invitrogen) according to manufacturer’s instructions. 
Agonist treatment 
For concentration dilution series, HEK293T cells co-transfected with 
OX1R-Rluc and OX1R-Venus were treated with apelin-13 or orexin-A in a 
concentration series from 10-5 to 10-12 M by ten-fold dilution for 18 min before 
BRET assay. While for time series, the same cells were treated with 10-6 M 
apelin-13 or orexin-A for 2, 6, 9, 13, 16, 23 min before BRET assay. 
TM peptide treatment 
The seven TM peptides of APJ were synthesized as described previously with 
a TAT sequence at N or C terminus to ensure peptides incorporating into the 
plasma membrane in correct direction[6, 19], as shown in supplemental table 1. 
Immediately before use, the peptides were solubilized in dimethyl sulfoxide 
(DMSO) and diluted in the DMEM medium to yield a final concentration of 1% 
DMSO. We verified that, no effect on cell viability was observed for each tested 
concentration of DMSO alone. Cells were incubated with the peptides 
mentioned above at 37 oC for 2 h prior to performing BRET analysis. 
BRET1 assay 
The BRET1 assay was performed as Pfleger et al. described[20]. In saturation 
assay, HEK293T cells were transiently co-transfected with constant amounts 
(1 μg) of plasmids encoding for OX1R-Rluc and increasing amounts (0.5–8 μg) 
of plasmids encoding for APJ-Venus. Forty-eight hours after transfection, the 
cells were rapidly washed twice in PBS, detached, and resuspended in the 
same buffer. Cell suspensions were distributed in duplicate into 96-well 
microplates; black plates (Corning 3651) for fluorescence measurement or 
white plates with white bottom (Corning 3600) for BRET determination. For 
BRET1 ratio measurement, coelenterazine h substrate (Molecular Probes) was 
added at a final concentration of 5 μM. Readings were performed after 1 min 
and the BRET signal was detected using the Mithras LB941 plate reader 
(Berthold Technologies, Bad Wildbad, Germany) that allows the sequential 
integration of the signals detected with two filter settings. Data were then 
represented as a normalized netBRET1 ratio versus the fluorescence value 
obtained from the Venus, normalized with the luminescence value of 
OX1R-Rluc expression 10 min after coelenterazine h incubation. The 
normalized netBRET1 ratio was defined as the BRET ratio for co-expressed 
Rluc and Venus constructs normalized against the BRET ratio for the Rluc 
expression construct alone in the same experiment: netBRET1 ratio = [(Venus 
emission at 530 ± 10 nm) / (Rluc emission 485 ± 10 nm)] – cf. The correction 
factor, cf. corresponds to (emission at 530 ± 10 nm) / (emission at 485 ± 10 nm) 
found with the receptor-Rluc construct expressed alone in the same 
experiment. BRET isotherms were fitted using a nonlinear regression equation 
assuming a single binding site, which provided BRETmax and netBRETmax 
values. The maximal value of BRET (BRETmax or netBRETmax) corresponds 
to the situation when all available donor molecules are paired up with acceptor 
molecules. 
Coimmunoprecipitation (Co-IP) 
Co-IP was conducted according to a standard method with minor 
modifications[21]. In brief, 10 μg plasmids were transfected into HEK293T cells, 
followed by culturing for 48 h. For cell lysis, cells were washed with ice-cold 
PBS for 3 times before adding the cell lysis buffer (Beyotime，P0013). Detach 
cells with cell scraper and lyse them using ultrasonic cell disrupter (100-200 w, 
work for 30 s and pause for 1 min, 3-4 times). To completely dissolve the 
membrane proteins, the cell lysis was turned upside down and centrifuged 
18,000 g for 30 min both in a 4 oC circumstance. Determine the protein 
concentration using a BCA protein concentration kit (TIANGEN, PA115) 
according manufacturer’s instructions. Co-IP was conducted using a Pierce 
Anti-HA Agarose kit (Thermo Scientific, 26181) as instructed. Dilute the 5× 
SDS sample buffer with precipitate suspended in 200 μl TBS buffer and then 
incubate the mixture for 10 min in a 37 oC water bath. Subsequently, conduct a 
Western Blot with a protocol described in Molecular Cloning: a laboratory 
manual (4th edition). The antibodies of HA (CST, 3724), Myc (CST, 2278) and 
beta-actin (CST, 3700) were diluted in 1:10,000, 1:500 and 1:2,000, 
respectively. While the HRP-conjugated secondary antibodies (Invitrogen, 
G21040 and G21234) were all diluted in 1:5,000. 
Immunostaining 
Culture the transfected cells overnight, and at the same time, treat the clean 
round coverslips with 0.1 % (w/v) poly-L-lysine (PLL) overnight as well. 
Passage cells to coverslips for a continuous culture for 24 h. Using 4 % 
formaldehyde diluted in warm PBS to fix cells for 15 min at room temperature 
and proceed with rinsing with PBS for three times, 5 min each. For 
immunostaining, Block specimen in blocking buffer (1× PBS, 5% normal serum 
5% BSA, 0.3% Triton™ X-100) for 60 min, and rinse the specimen briefly with 
PBS. Incubate the primary antibody of HA (CST, 2367) with dilution 1:100 
overnight at 4 oC followed by rinse slips three times in 1× PBS for 5 min each. 
Next, incubate the specimen with cy3-conjucgated secondary antibody 
(Invitrogen, A10521) with dilution of 1:50 for 2 h away from light at room 
temperature. After rinsing three times in 1X PBS for 5 min each, coverslip 
slides with Mounting medium with DAPI (Duolink, Art no 82040) and allow 
mountant to cure overnight protected from light at room temperature. Slides 
were scanned with confocal microscopy (Leica TCS SP8).  
Statistical analysis 
Statistical analysis was carried out with GraphPad Prism software, and all the 
data were showed as mean ± SEM. For comparing two groups of data, 
two-tailed, unpaired Student’s t test was used. The difference was considered 
significant when p<0.05. 
 
Results 
1. APJ and OX1R form constitutive heterodimers 
To investigate whether APJ and OX1R dimerize or not, we employed 
bioluminescence resonance energy transfer (BRET)1 assay. OX1R-Rluc 
(Renilla luciferase) and APJ-Venus were co-expressed in HEK293T cells, with 
combination of KOR-Rluc and APJ-Venus, KOR196-Rluc and NSTR1-Venus 
as the positive and negative control, respectively[17, 18]. BRET saturation 
assay showed that APJ and OX1R could dimerize with each other (Fig. 1A). To 
verify the BRET results, co-immunoprecipitation (Co-IP) was implemented. 
From Fig. 1B, we can find that when 3×HA-APJ and OX1R-Myc were 
expressed in the same HEK293T cell, OX1R-Myc could be found in 
sedimentation precipitated with anti-HA antibody (Fig 1B). However, not any 
OX1R-Myc could be co-precipitated using the same method when the two 
fused protein expressed solo then mixed together (Fig 1B, mix). Co-IP assay 
indicated that APJ and OX1R constitute a complex. These results robustly 
demonstrated that APJ and OX1R could heterodimerize.  
We wonder the effect of ligand binding on dimerization of APJ and OX1R. 
First, different concentration of apelin-13 (the agonist of APJ) and orexin-A (the 
agonist of OX1R) were applied on cells expressing both APJ-Venus and 
OX1R-Rluc following by BRET assay. However, no correlation trend could be 
found between BRET ratio and the concentration gradient (Fig. S1A), 
suggesting that ligand binding didn’t affect the dimerization of these two 
receptors. In addition, there is no effect on the time series either (Fig. S1B). 
Together, these results indicate that APJ and OX1R can constitutively form a 
heterodimer. 
 
2. APJ dimerize with OX1R mainly through its transmembrane peptide 4 and 
5 
The interactive interface of GPCRs remains to be clarified, especially for 
heterodimers[4]. To dissect the interactive interface of APJ and OX1R, the 
seven transmembrane peptides (TMs) of APJ used to disrupt the interaction of 
APJ and OX1R were in vitro synthesized (supplemental table 1). Combined 
with BRET technique, the mixture of all seven TMs (10, 20 or 40 μM each) was 
exerted to HEK293T cells expressing OX1R-Rluc and APJ-Venus, and we 
found that 20 and 40 μM could interfere with the heterodimer formation (Fig. 
2A). With the same method, 20 μM of each TM was applied separately instead 
of a mixture, we successfully found out that TM 4 and 5 of APJ could disrupt 
the dimerization of APJ and OX1R significantly (Fig. 2B). These results 
demonstrated that TM 4 and 5 of APJ mainly constitute the interaction 
interface with OX1R. 
 
3. APJ and OX1R could co-internalize subject to either apelin-13 or orexin-A 
Given the heterodimerization of APJ and OX1R, we speculated that the 
heterodimer may co-internalize when stimulate with the agonists. To test this, 
we first co-express OX1R-Venus and 3×HA-APJ in HEK293T cells following by 
immunostaining with HA antibody. As expected, both OX1R-Venus and 
3×HA-APJ co-localize on the plasma membrane (Fig. 3). Subsequently, the 
cells were incubated with apelin-13 or orexin-A, or both agonists for 30 min. 
Interestingly, either apelin-13 or orexin-A could result in internalization of the 
heterodimer (Fig. 4A). Dual agonists incubation lead to even more serious 
internalization, whereas the vehicle saline had not any internalization with the 
same incubation time (Fig. 4A). These results indicate that the dimer of APJ 
and OX1R could co-internalize subject to either agonists (apelin-13 or 
orexin-A).  
 
4. Dimerization is essential for co-internalization of APJ and OX1R 
We next explored if the interface peptides could impede co-internalization of 
heterodimers. As shown above, both application of orexin-A and apelin-13 
could cause the co-internalization of the dimer between APJ and OX1R (Fig. 
4A). However, when TM 4 and 5 of APJ were applied simultaneously, the 
co-internalization of the dimer was disrupted, instead, application of either 
apelin-13 or orexin-A only internalize the corresponding protomer after 
incubation for 30 min (Fig. 4B). This suggests that the dimerization is essential 
for co-internalization of APJ and OX1R, and TM 4 and 5 of APJ worked as the 
interaction interface, consistent with the preceding results.  
 
Discussion 
In this study, we found that APJ and OX1R could form a heterodimer, which 
served as an entity for co-internalization in HEK293T cells. In addition, TM 4 
and 5 of APJ may be the interface in its dimerization with OX1R and these in 
vitro synthesized peptides could disrupt the co-internalization of the 
heterodimers, further demonstrating the significant roles of APJ’s TM 4 and 5 
in its interaction with OX1R.  
It has been known that GPCR signaling can be modulated at multiple levels, 
in which one of the most important modulations is the internal interactions of 
GPCRs themselves[22, 23]. Interactive GPCR can form a homomer or 
heteromer that can exhibit properties distinct from those of the protomers, such 
as altering the binding properties of protomer-selective ligands, changing the 
signal transduction and leading to novel trafficking properties[4]. Here we 
found a completely new GPCR heteromer of APJ and OX1R, and more 
intriguingly, agonist of either protomer can stimulate the co-internalization of 
both protomers (Fig. 1 and 4). Similar to this discovery, studies have reported 
that morphine triggers the internalization of MOR1D and GRPR and that 
sst2A-selective ligand L-779976 induces internalization of sst2A-MOR1 
heterodimer[5, 24]. However, it should be noted that co-internalization of both 
above heterodimers can only be induced by the agonist specific to one of the 
protomer but not by the other, distinct to APJ-OX1R heteromers. The 
internalization of GPCRs are initiated with phosphorylation of receptors and 
then preceded with recruiting arrestins[25]. We speculate that one of the 
possible mechanisms is APJ-OX1R co-internalize as an entirety due to the 
stable interaction albeit only one protomer is phosphorylated, the other 
possibility is conformation of one protomer is allosterically modulated by the 
other, resulting that both protomer are phosphorylated by the same kinase. 
Further work needs to be addressed on phosphorylation of APJ and OX1R 
when co-internalized. 
Nevertheless, sufficient study on dimerized interface is not only crucial to 
reveal the molecular rules on GPCR-GPCR interactions, but provides potential 
tools to manipulate them for pharmacology. In general, the hydrophobic 
helices work as the interaction interface but sometimes it depends. In terms of 
previous study, three transmembrane domains (TMD) are interactive hotspot, 
which are TM1-2, TM4-5, and the C terminus. Specifically, TM1-2 mainly 
participate in the homodimerization, typically in homodimers such as 
neurotensin 1 receptor, M3 muscarinic receptor, rhodopsin, and APJ[8, 19, 
26-28]. Except for homodimers of M3 muscarinic receptor, rhodopsin and 
angiotensin II type 1 receptor[8, 27-29], TM4-5 are directly involved in 
heteromerization of A2A Adenosine and D2 Dopamine Receptor[3]. The C 
terminus of MOR1D, D1 and DOR act as the interface of heterodimerization 
with GRPR, D2 and MOR[6, 7, 30]. Using bioluminescence resonance energy 
transfer (BRET) and immunostaining, we found that TM4-5 of APJ may serve 
the dimerization interface of APJ with OX1R (Fig. 2 and 4). This finding added 
new evidence that TM4-5 are significant interfaces in GPCR heteromerization. 
In contrast to APJ’s homomerization, in which TM1-4 rather than TM 5-7 are 
indispensable for the formation of homomers[19], TM4 and 5 of APJ involve in 
the heteromerization with OX1R. We propose that the interactive TM domains 
differentially participate in homomerization and heteromerization for the same 
GPCR, although in this case TM4 is essential both for homomer and 
heteromer formation of APJ.  
Our results suggested that apelin and orexin system may work 
synergistically. To investigate this question, first of all, one must figure out if 
APJ and OX1R could dimerize in vivo. Several methods can be employed, 
including antibody-aided or ligand-aided time-resolved fluorescence RET 
(TR-FRET), antibodies-aided proximity ligation assays and 
co-immunoprecipitation and so on[4]. To address the physiological roles of the 
dimer especially roles in stress response[10, 15], a direct method is to interrupt 
the dimer. Interfering peptides discovered in this study may provide a choice. 
To summarize, we found that in HEK293T cells, APJ and OX1R could form a 
heterodimer, which internalized when subject to agonist to either protomer of 
the dimer. Co-inernalization of the dimer could be disrupted by interfering 
peptides of TM4 and 5 of APJ, which serves as the interactive interface of 
APJ-OX1R heterodimer. These findings suggest that APJ and OX1R system 
may mutually affected and provide more clues on the study of GPCR 
dimerization interfaces.  
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Figure 1. Characterization of the heterodimerization between APJ and OX1R 
in HEK293T cells. (A) Saturating BRET assay. In cells expressing a fixed 
amount receptor1-Rluc and increasing amounts of receptor2-Venus, BRET 
was measured. (B) Co-IP. 3×HA-APJ and OX1R-Myc were co-expressed in 
the same cells, or expressed individually and mixed together as the negative 
control, before performing immunoprecipitation (IP) with HA antibody. Pairs of 
OX1R and kappa opioid receptor (KOR) were used as positive control. Arrows 
indicate positions of anticipated bands. IB, immunoblot. 
 
Figure 2. Transmembrane peptide (TM) 4 and 5 of APJ are involved in the 
dimerization with OX1R. (A) Minimal concentration of TM that could effectively 
disrupt the heterodimerization was determined using a concentration gradient 
of gross TMs as indicated to incubate with HEK293T cells co-expressing 
OX1R-Rluc and APJ-Venus before BRET was measured. (B) 20 μM of each 
TM of APJ were incubated with HEK293T cells co-expressing OX1R-Rluc and 
APJ-Venus following BRET measurement. Data represent the mean ± SEM of 
at least three independent experiments. The statistical significance between 
vehicle and TM was assessed using an unpaired student’s t-test (*P < 0.05). 
ns, not statistically significant. 
 
Figure 3. APJ and OX1R co-localize on the plasma membrane of HEK293T. 
OX1R tagged with Venus fluorescent protein and APJ tagged with 3×HA were 
expressed individually or together in HEK293T cells, followed by 
immunostaining. DAPI (blue), Venus (green) and Cy3 (red) show nuclei, OX1R 
and APJ, respectively. 
 
Figure 4. Co-internalization of APJ-OX1R heterodimer. (A) apelin-13 or 
orexin-A stimulate the co-internalization of the dimer. HEK293T cells 
co-expressing OX1R-Venus and 3×HA-APJ were stimulated for 30 min with 
100 nM of apelin-13 and/or 1 μM of orexin before imaging. (B) Blockage the 
dimerization prevents the co-internalization. HEK293 cells co-expressing 
OX1R-Venus and 3×HA-APJ were incubated with one kind of agonists 
combined with the TM 4 and 5 of APJ at the same time. 
 
Supplementary figure 1. The effect of ligand stimulation on APJ and OX1R 
heterodimerization. (A) Different concentration of ligands has no effect on 
heterodimerization reflected by BRET ratio when stimulated for 18 min. (B) 
10-6 M ligands have no effect on heterodimerization either. 
 
Supplementary table 1. Amino acid sequences of synthetic peptides derived 
from the transmembrane domains of human APJ 
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